Fatal interstitial lung disease induced by rituximab-containing chemotherapy, treatment with TNF-α antagonist and cytokine profiling: A case-report and review of the literature

Journal of Clinical Pharmacy and Therapeutics

Volumn 38, Issue 3, 2013, Pages 249-253

  Wu, Yongkang ^a   Jia, Yongqian ^a   Xu, Juan ^a   Shuai, Xiao ^a   Wu, Yu ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

cytokine; IL 6; interstitial lung disease; rituximab; TNF

Indexed keywords

AMPHOTERICIN; AZITHROMYCIN; C REACTIVE PROTEIN; CASPOFUNGIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FOSCARNET SODIUM; INTERLEUKIN 6; MEPREDNISONE; PREDNISONE; PROCALCITONIN; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VINCRISTINE;

AGED; CANCER CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CD4 CD8 RATIO; COUGHING; DISEASE EXACERBATION; DISTRESS SYNDROME; DYSPNEA; FATALITY; FEMALE; FEVER; HUMAN; INTERSTITIAL LUNG DISEASE; LARGE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RESPIRATORY FAILURE; REVIEW; STEROID THERAPY;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CYTOKINES; FATAL OUTCOME; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; LYMPHOMA, LARGE B-CELL, DIFFUSE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84876674994     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12052     Document Type: Review

References (28)

1. Cheson BD, Leonard JP,. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med, 2008; 359: 613-626.
2. Buske C, Hoster E, Dreyling M, et al,. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia, 2009; 23: 153-161.
3. Zhou X, Hu W, Qin X,. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist, 2008; 13: 954-966.
4. Davis TA, Grillo-Lopez AJ, White CA, et al,. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol, 2000; 18: 3135-3143.
5. Rehwald U, Schulz H, Reiser M, et al,. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood, 2003; 101: 420-424.
6. Burton C, Kaczmarski R, Jan-Mohamed R,. Interstitial pneumonitis related to rituximab therapy. N Engl J Med, 2003; 348: 2690-2691; discussion 2690-2691.
7. Wagner SA, Mehta AC, Laber DA,. Rituximab-induced interstitial lung disease. Am J Hematol, 2007; 82: 916-919.
8. Herishanu Y, Polliack A, Leider-Trejo L, Grieff Y, Metser U, Naparstek E,. Fatal interstitial pneumonitis related to rituximab-containing regimen. Clin Lymphoma Myeloma, 2006; 6: 407-409.
9. Liu X, Hong XN, Gu YJ, Wang BY, Luo ZG, Cao J,. Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma. Leuk Lymphoma, 2008; 49: 1778-1783.
10. Liote H, Liote F, Seroussi B, Mayaud C, Cadranel J,. Rituximab-induced lung disease: a systematic literature review. Eur Respir J, 2010; 35: 681-687.
11. Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ostor AJ,. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford), 2012; 51: 653-662.
12. Ennishi D, Terui Y, Yokoyama M, et al,. Increased incidence of interstitial pneumonia by CHOP combined with rituximab. Int J Hematol, 2008; 87: 393-397.
13. Katsuya H, Suzumiya J, Sasaki H, Ishitsuka K, Shibata T, Takamatsu Y, Tamura K,. Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leuk Lymphoma, 2009; 50: 1818-1823.
14. Coiffier B, Lepage E, Briere J, et al,. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 2002; 346: 235-242.
15. Kanelli S, Ansell SM, Habermann TM, Inwards DJ, Tuinstra N, Witzig TE,. Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. Leuk Lymphoma, 2001; 42: 1329-1337.
16. Chaumais MC, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, Deschenes G,. Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol, 2009; 24: 1753-1755.
17. Kishi J, Nanki T, Watanabe K, Takamura A, Miyasaka N,. A case of rituximab-induced interstitial pneumonitis observed in systemic lupus erythematosus. Rheumatology (Oxford), 2009; 48: 447-448.
18. Huang YC, Liu CJ, Liu CY, et al,. Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma. Ann Hematol, 2011; 90: 1145-1151.
19. Cooper N, Arnold DM,. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol, 2010; 149: 3-13.
20. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A,. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood, 1999; 94: 2217-2224.
21. Sato K, Nagai T, Izumi T, Ohmine K, Ozaki K, Muroi K, Ozawa K,. Rituximab-induced interstitial pneumonia due to CD8-positive T cell infiltration. Acta Haematol, 2012; 128: 107-109.
22. Schmidt K, Martinez-Gamboa L, Meier S, et al,. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther, 2009; 11: R111.
23. Vasakova M, Sterclova M, Kolesar L, et al,. Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases. Scand J Immunol, 2009; 69: 268-274.
24. Bargagli E, Galeazzi M, Bellisai F, Volterrani L, Rottoli P,. Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration, 2008; 75: 346-349.
25. Zhang M, Qian J, Xing X, Kong FM, Zhao L, Chen M, Lawrence TS,. Inhibition of the tumor necrosis factor-alpha pathway is radioprotective for the lung. Clin Cancer Res, 2008; 14: 1868-1876.
26. Kuroki M, Noguchi Y, Shimono M, et al,. Repression of bleomycin-induced pneumopathy by TNF. J Immunol, 2003; 170: 567-574.
27. Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P,. The late adverse events of rituximab therapy-rare but there!. Leuk Lymphoma, 2009; 50: 1083-1095.
28. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La Greca G,. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet, 2000; 356: 26-30.